On November 3, 2022, Iveric Bio announced that it had submitted the first part of the “rolling review” for the new drug application (NDA) of avacincaptad pegol (ACP, also known as Zimura)Read More…
29Dec/22
10Nov/22
First Potential Oral Monotherapy for Paroxysmal Nocturnal Hemoglobinuria
Novartis recently announced that its new drug iptacopan has achieved positive results in a Phase 3 clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), with patients’ hemoglobin levels increasing significantlyRead More…
14Oct/22
Acetylcholine Receptor (AChR) Antibody-positive Myasthenia Gravis, from Antibody to Complement
Myasthenia gravis (MG) is an autoimmune disease characterized by an acquired neuromuscular junction transmission disorder mediated by autoantibodies. MG patients are mainly characterized by fluctuating weakness and fatigue of skeletal muscles, withRead More…
22Sep/22
C3 Glomerulopathy – Complement-Driven Kidney Disease
In 2013, experts reached a consensus to adopt the term C3 glomerulopathy (C3G) to define a group of rare kidney diseases driven by dysregulation of the alternative complement pathway, mediated by geneticRead More…
18Aug/22
Features of the Three Complement Activation Pathways
There are three complement activation pathways in the complement system, that is, the classical pathway, the alternative pathway, and the lectin pathway. The three pathways have different origins, but they cross eachRead More…
21Jul/22
Pegcetacoplan, a Peptide Drug Targeting Complement C3, Helps in the Treatment of Ophthalmic Diseases and Rare Diseases
The complement system, also known as the complement cascade, is a crucial component of both the innate and the adaptive immune systems, which can assist or supplement antibodies and phagocytes to clearRead More…
15Jun/22
FDA Approved the First Long-acting Complement C5 Inhibitor for the Treatment of Myasthenia Gravis!
On April 28, AstraZeneca released news that its subsidiary Alexion’s new drug Ultomiris (Ravulizumab) was approved by the FDA for the treatment of anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) adultRead More…
19May/22
Aptamer Drug Conjugate (ApDC): Advantages and Applications
Targeted therapy is the strategies employed by of most current tumor drugs, but in fact many of them have poor selectivity and certain off-target toxicity. Correspondingly, an approach that becomes increasingly prominentRead More…
21Apr/22
Atypical Hemolytic Uremic Syndrome and the Complement System
According to statistics, the prevalence of atypical hemolytic uremic syndrome (aHUS) is about seven in one million. The majority of aHUS have complement-related factor gene mutations, and the etiology of about 6%Read More…
12Mar/22
C5AR1: A Potential Target in The Complement System for COVID-19 Drug Development
With the global pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) still ongoing, the prevention and treatment of COVID-19 has become a research focus inRead More…